Literature DB >> 27375219

Mutations Causing Slow-Channel Myasthenia Reveal That a Valine Ring in the Channel Pore of Muscle AChR is Optimized for Stabilizing Channel Gating.

Xin-Ming Shen1, Tatsuya Okuno2, Margherita Milone3, Kenji Otsuka2, Koji Takahashi4, Hirofumi Komaki4, Elizabeth Giles5, Kinji Ohno3,2, Andrew G Engel3.   

Abstract

We identify two novel mutations in acetylcholine receptor (AChR) causing a slow-channel congenital myasthenia syndrome (CMS) in three unrelated patients (Pts). Pt 1 harbors a heterozygous βV266A mutation (p.Val289Ala) in the second transmembrane domain (M2) of the AChR β subunit (CHRNB1). Pts 2 and 3 carry the same mutation at an equivalent site in the ε subunit (CHRNE), εV265A (p.Val285Ala). The mutant residues are conserved across all AChR subunits of all species and are components of a valine ring in the channel pore, which is positioned four residues above the leucine ring. Both βV266A and εV265A reduce the amino acid size and lengthen the channel opening bursts by fourfold by enhancing gating efficiency by approximately 30-fold. Substitution of alanine for valine at the corresponding position in the δ and α subunit prolongs the burst duration four- and eightfold, respectively. Replacing valine at ε codon 265 either by a still smaller glycine or by a larger leucine also lengthens the burst duration. Our analysis reveals that each valine in the valine ring contributes to channel kinetics equally, and the valine ring has been optimized in the course of evolution to govern channel gating.
© 2016 WILEY PERIODICALS, INC.

Entities:  

Keywords:  acetylcholine receptors; congenital myasthenic syndrome; ion channel; patch-clamp; slow-channel syndrome

Mesh:

Substances:

Year:  2016        PMID: 27375219      PMCID: PMC5021579          DOI: 10.1002/humu.23043

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  31 in total

1.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.

Authors:  Daniel C Koboldt; Qunyuan Zhang; David E Larson; Dong Shen; Michael D McLellan; Ling Lin; Christopher A Miller; Elaine R Mardis; Li Ding; Richard K Wilson
Journal:  Genome Res       Date:  2012-02-02       Impact factor: 9.043

2.  Energy and structure of the M2 helix in acetylcholine receptor-channel gating.

Authors:  Archana Jha; Prasad Purohit; Anthony Auerbach
Journal:  Biophys J       Date:  2009-05-20       Impact factor: 4.033

3.  Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome.

Authors:  C M Harper; A G Engel
Journal:  Ann N Y Acad Sci       Date:  1998-05-13       Impact factor: 5.691

4.  Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit.

Authors:  K Ohno; H L Wang; M Milone; N Bren; J M Brengman; S Nakano; P Quiram; J N Pruitt; S M Sine; A G Engel
Journal:  Neuron       Date:  1996-07       Impact factor: 17.173

5.  Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity.

Authors:  S M Sine; K Ohno; C Bouzat; A Auerbach; M Milone; J N Pruitt; A G Engel
Journal:  Neuron       Date:  1995-07       Impact factor: 17.173

6.  Fast events in single-channel currents activated by acetylcholine and its analogues at the frog muscle end-plate.

Authors:  D Colquhoun; B Sakmann
Journal:  J Physiol       Date:  1985-12       Impact factor: 5.182

7.  Single acetylcholine-activated channels show burst-kinetics in presence of desensitizing concentrations of agonist.

Authors:  B Sakmann; J Patlak; E Neher
Journal:  Nature       Date:  1980-07-03       Impact factor: 49.962

8.  Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit.

Authors:  K Ohno; D O Hutchinson; M Milone; J M Brengman; C Bouzat; S M Sine; A G Engel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome.

Authors:  Amina Chaouch; Juliane S Müller; Velina Guergueltcheva; Marina Dusl; Ulrike Schara; Vidosava Rakocević-Stojanović; Christopher Lindberg; Rosana H Scola; Lineu C Werneck; Jaume Colomer; Andres Nascimento; Juan J Vilchez; Nuria Muelas; Zohar Argov; Angela Abicht; Hanns Lochmüller
Journal:  J Neurol       Date:  2011-08-07       Impact factor: 4.849

10.  Detection and trapping of intermediate states priming nicotinic receptor channel opening.

Authors:  Nuriya Mukhtasimova; Won Yong Lee; Hai-Long Wang; Steven M Sine
Journal:  Nature       Date:  2009-04-01       Impact factor: 49.962

View more
  7 in total

1.  Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine.

Authors:  Hacer Durmus; Heinrich Sticht; Serdar Ceylaner; Said Hashemolhosseini; Feza Deymeer
Journal:  Acta Neurol Belg       Date:  2020-10-08       Impact factor: 2.396

2.  Mitochondrial disorder mimicking rheumatoid disease.

Authors:  Josef Finsterer; Madleine Melichart-Kotig; Adelheid Woehrer
Journal:  Z Rheumatol       Date:  2019-11       Impact factor: 1.372

3.  Determinants of the repetitive-CMAP occurrence and therapy efficacy in slow-channel myasthenia.

Authors:  Li Di; Hai Chen; Yan Lu; Duygu Selcen; Andrew G Engel; Yuwei Da; Xin-Ming Shen
Journal:  Neurology       Date:  2020-09-09       Impact factor: 9.910

4.  High Throughput Random Mutagenesis and Single Molecule Real Time Sequencing of the Muscle Nicotinic Acetylcholine Receptor.

Authors:  Paul J Groot-Kormelink; Sandrine Ferrand; Nicholas Kelley; Anke Bill; Felix Freuler; Pierre-Eloi Imbert; Anthony Marelli; Nicole Gerwin; Lucia G Sivilotti; Loren Miraglia; Anthony P Orth; Edward J Oakeley; Ulrich Schopfer; Sandra Siehler
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

5.  Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients.

Authors:  Grace McMacken; Roger G Whittaker; Teresinha Evangelista; Angela Abicht; Marina Dusl; Hanns Lochmüller
Journal:  J Neurol       Date:  2017-11-30       Impact factor: 4.849

6.  Congenital myasthenic syndromes.

Authors:  Josef Finsterer
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

7.  Slow-channel myasthenia due to novel mutation in M2 domain of AChR delta subunit.

Authors:  Xin-Ming Shen; Margherita Milone; Hang-Long Wang; Brenda Banwell; Duygu Selcen; Steven M Sine; Andrew G Engel
Journal:  Ann Clin Transl Neurol       Date:  2019-09-27       Impact factor: 4.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.